HER2-Negative Breast Cancer Neoadjuvant Electrothermal Therapy Clinical Trial
Research Background
Patients with HER2‑negative, stage II–III breast cancer have limited treatment options beyond standard neoadjuvant chemotherapy. Electrothermal therapy delivers selective heat to tumor tissue, promoting cell death and is expected to synergize with existing therapies.
Clinical Design
The study employs a multi‑stage design that runs Phase 2 and Phase 3 concurrently. It was initiated on 2023‑02‑20 and is currently in an ACTIVE_NOT_RECRUITING status, indicating enrollment is complete. The primary endpoints and projected completion date are not specified in the source and require confirmation.
Differentiation and Expected Benefits
Electrothermal therapy increases intratumoral blood flow, enhancing drug penetration, and induces direct thermal cell injury. This mechanism may amplify chemotherapy efficacy while minimizing adverse effects.
Market and Clinical Significance
HER2‑negative breast cancer accounts for approximately 70 % of all breast cancer cases, and resistance to existing treatments remains a challenge. If successful, a combined regimen that includes electrothermal therapy could become a new standard of care.
Future Outlook
No financial partnerships or corporate collaborations have been disclosed to date. However, positive trial outcomes could trigger heightened investment interest from medical‑device companies, and may lead to co‑development agreements with multinational pharmaceutical firms.
Integrating electrothermal therapy into a neoadjuvant strategy for HER2‑negative breast cancer could improve therapeutic efficacy and, upon clinical success, generate revenue growth potential for associated medical‑device and biotech companies. The development of a novel treatment and its progression through clinical trials are likely to influence hiring demand and research investment in the medical‑device and pharmaceutical sectors.
Source: ClinicalTrials.gov (api_ct)